other material
confidence high
sentiment positive
materiality 0.90
Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML
Actinium Pharmaceuticals, Inc.
- Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).
- Event-free survival HR=0.22 (78% risk reduction, p<0.0001).
- Iomab-B doubled 1-year OS (26.1% vs 13.1%) and median OS (6.4 vs 3.2 months).
- Sepsis rate 4x lower (6.1% vs 28.6%); 100% engraftment in Iomab-B arm.
- Patients achieving dCR had 92% 1-year and 60% 2-year survival.